Archive · 21 Nov 2025
Biological E's Pneubevax 14 Wins WHO Pre-Qualification
A company called Biological E has made a new vaccine that protects babies from 14 types of serious infections caused by bacteria called pneumococcus.
The World Health Organization has said this vaccine is good to use, which means more babies around the world can get it to stay healthy.
Biological E (BE) receives WHO's pre-qualification for Pneubevax 14 vaccine
Vaccine protects against 14 pneumococcal serotypes, including 22F and 33F
Administered to infants from six weeks of age to prevent serious diseases
Clinical studies show good safety profile and robust immune responses
WHO PQ enhances global access and supply security for the vaccine
- Who
- Biological E (BE)
- What
- Received WHO pre-qualification for Pneubevax 14 vaccine
- When
- November 20, 2025
- Where
- Globally, with a focus on India
- Why
- To enhance global access and supply security for the vaccine
Proponents of the vaccine
Potential critics
Global access
Proponents of the vaccine
The WHO pre-qualification will expand global access to reliable pneumococcal vaccines, benefiting children worldwide.
Potential critics
Potential critics might argue that the focus on global access could lead to delays in domestic supply.
- Vaccine Name
- Pneubevax 14
- Targeted Serotypes
- 14 (including 22F and 33F)
- Age for Administration
- Infants from six weeks of age
- Diseases Prevented
- Pneumonia, meningitis, sepsis
- WHO Pre-Qualification Status
- Received
